With a heightened awareness of the potential retention issues with certain gadolinium-based contrast agents, patients who feel they’ve been harmed are seeking support groups and agent manufacturers are facing more questions, according to an article from investigative journalism site ProPublica.
Both GE Healthcare, makers of Omniscan, and Bayer HealthCare, makers of Magnevist, said they are monitoring the situation but that studies had not yet proven a clinical impact associated with the retained gadolinium. For more from ProPublica, click the link below:
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.